Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Curium Pharma to Acquire Lantheus Holdings in $8 Billion Deal, Expanding Radiopharmaceutical Market Dominance

Fineline Cube Aug 5, 2026
Company Deals

Alphamab Oncology Secures $2.2B Deal with Pathos AI for JSKN016 Global Licensing

Fineline Cube Aug 5, 2026
Company Deals

Hunan Zonsen PepLib Biotech Secures Over RMB 300 Million in Series C Financing

Fineline Cube Aug 5, 2026
Company Deals

Siemens Healthineers and Cleveland Clinic Announce 10-Year Strategic Partnership

Fineline Cube Aug 4, 2026
Company Deals

Apeloa Pharmaceutical and METiS Therapeutics Announce Strategic CDMO Partnership

Fineline Cube Aug 4, 2026
Drug Medical Device Policy / Regulatory

NMPA Proposes Framework for Synchronized Development of Anti-Tumor Drugs and Companion Diagnostics

Fineline Cube Aug 4, 2026
Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Fineline Cube Aug 6, 2026
Company Drug

Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership

Fineline Cube Aug 5, 2026
Company Drug

Zhejiang Huahai Receives FDA ANDA Approval for Generic Tecfidera

Fineline Cube Oct 28, 2022

China-based Zhejiang Huahai Pharmaceutical Co., Ltd (SHA: 600521) announced that it has received Abbreviated New...

Company Deals

Novartis Expands Strategic Collaboration with Bo’Ao Lecheng Pilot Zone

Fineline Cube Oct 28, 2022

Novartis (NYSE: NVS) announced a further strategic collaboration with the Bo’Ao Lecheng Medical Tourism Pilot...

Company Deals

Salubris Partners with Alpha Molecular for AI-Driven Obesity Drug Development

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with compatriot...

Company

RemeGen Reports 397.47% YOY Revenue Growth in Q3 2022

Fineline Cube Oct 28, 2022

China-based pharma firm RemeGen (HKG: 9995) released its Q3 2022 financial report, showing significant growth...

Company Drug

Innovent’s Parsaclisib Filed for Marketing Approval in China

Fineline Cube Oct 28, 2022

China’s Center for Drug Evaluation (CDE) has received a marketing approval application for Innovent Biologics...

Company Drug

Proheal Pharmaceuticals Initiates Clinical Study for PHP1003 in Thyroid-Associated Ophthalmopathy

Fineline Cube Oct 28, 2022

Proheal Pharmaceuticals, a Suzhou-based developer of drugs for ophthalmology and autoimmune diseases, announced the first...

Company Drug

HutchMed Initiates Phase II/III Study for Elunate and Tyvyt in Renal Cell Carcinoma

Fineline Cube Oct 28, 2022

China-based Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) announced the initiation of a Phase...

Company

Shanghai Pharmaceuticals Reports 12.86% YOY Revenue Growth in Q3 2022

Fineline Cube Oct 28, 2022

Shanghai Pharmaceuticals (HKG: 2607, SHA: 601607) released its Q3 2022 financial report, recording RMB 62.904...

Company Drug

Recbio’s Neoadjuvant HPV Vaccine Accepted for Review by NMPA

Fineline Cube Oct 28, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced that a clinical trial...

Company Drug

Kintor Completes Enrollment for GT20029 Phase I Study in US

Fineline Cube Oct 28, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of enrollment for a Phase I...

Company Drug

Alphamab Oncology Gains NMPA Approval for JSKN003 Clinical Trial

Fineline Cube Oct 28, 2022

Alphamab Oncology (HKG: 9966) announced that it has received approval from the National Medical Products...

Company Drug

WinHealth’s Ravicti Receives Orphan Drug Designation in Taiwan

Fineline Cube Oct 28, 2022

China-based Hong Kong WinHealth Pharma Group Ltd announced that its Swiss partner Immedica Pharma AB’s...

Company Drug

Lee’s Pharmaceutical’s NVK-002 Shows Strong Results in Phase III CHAMP Study

Fineline Cube Oct 28, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622) announced that...

Company Drug

CSPC’s Antibody-Drug Conjugate SYS6002 Gains CDE Approval for Clinical Study

Fineline Cube Oct 28, 2022

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company

Luye Pharma’s Long-Acting IL-4Rα Antibody BA2101 Gains CDE Approval

Fineline Cube Oct 28, 2022

China-based Luye Pharma Group (HKG: 2186) announced that its controlling subsidiary Shandong Boan Biotechnology Co.,...

Company Drug

Ausper Biopharma’s COVID-19 Nasal Spray Antibody Gets NMPA Approval

Fineline Cube Oct 28, 2022

Ausper Biopharma Inc., a Hangzhou-based developer of hepatitis B virus (HBV) drugs, announced that its...

Company

Merck’s Q3 Sales Rise on Key Drug Performances, China Growth

Fineline Cube Oct 28, 2022

US-based Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) reported its Q3 2022 financial results,...

Company Deals

Salubris Partners with Anlong Bio for Small Nucleic Acid Drugs in Hypertension

Fineline Cube Oct 28, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has entered into a partnership with Beijing...

Policy / Regulatory

Shanghai Launches Inhaled COVID-19 Vaccine Booster Program

Fineline Cube Oct 28, 2022

On October 25, Shanghai began accepting patient reservations for the inhalable recombinant COVID-19 vaccine (adenovirus...

Company Drug

Ocumension Initiates Second Phase III Denali Study for OT-301 in US

Fineline Cube Oct 27, 2022

China-based Ocumension Therapeutics (HKG: 1477) announced the initiation of a second Phase III Denali study...

Posts pagination

1 … 647 648 649 … 704

Recent updates

  • CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer
  • Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance
  • Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations
  • Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets
  • Leads Biolabs’ Trispecific T-Cell Engager LBL-051 Enters Phase Ia Trial for Refractory Autoimmune Diseases Through Oblenio Bio Partnership
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

CSPC Pharmaceutical’s NDA for Anbenitamab-HB1801 Combination Accepted by China NMPA as Neoadjuvant Therapy for HER2+ Breast Cancer

Company

Biogen Reports Q2 2026 Revenue of $2.74B, Growth Portfolio Surges 24% Led by Strong LEQEMBI and SKYCLARYS Performance

Company

Bayer Reports Q2 2026 Sales of EUR 10.87B, Driven by Strong Nubeqa and Kerendia Growth Despite Xarelto and Eylea Patent Expirations

Company

Takeda Reports Q1 FY2026 Revenue of JPY 1.22 Trillion, Outlines Growth Strategy Centered on Three Key Pipeline Assets

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.